Skip to main content
. Author manuscript; available in PMC: 2022 Jul 25.
Published in final edited form as: Clin Cancer Res. 2022 Mar 1;28(5):903–914. doi: 10.1158/1078-0432.CCR-21-2547

Figure 2.

Figure 2.

ORR rate (A), best reduction from baseline in the SLD with pembrolizumab monotherapy (B) and acalabrutinib + pembrolizumab combination therapy (C), progression-free survival (D), and overall survival (E) by the treatment group. CR, complete response; ORR, overall response rate; PR, partial response; SLD, sum of longest diameters.